International Isotopes (INIS) AI Stock Analysis

• Market Cap: $29.05M
• Dividend Yield: N/A
• Average Volume (3M): 137.10K
• Price to Earnings (P/E): 290.0
• Beta (1Y): 0.67
• Revenue Growth: 21.26%
• EPS Growth: N/A
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 528,104,100
• 10 Day Avg. Volume: 115,354
• 30 Day Avg. Volume: 137,096
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.64
• Enterprise Value/Revenue: 3.24
• Enterprise Value/Gross Profit: 6.99
• Enterprise Value/Ebitda: 54.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: $0.00 ▼(-100.00% Downside)

International Isotopes' overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant financial challenges, including declining profitability and high leverage. Technical indicators suggest bearish momentum, and the stock appears overvalued based on its P/E ratio. These factors contribute to a low overall stock score.

International Isotopes Business Overview & Revenue Model

Company Description

International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally. It operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. It offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources. The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications. The Radiological Services segment provides flood source disposal and gemstones processing services. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. It sells its products directly to end users and distributors. International Isotopes Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.

How the Company Makes Money

International Isotopes generates revenue through multiple key streams, including the sale of radiopharmaceuticals, stable isotopes, and related services. The company produces and sells a range of isotopes utilized in medical imaging and cancer treatment, which are critical for healthcare providers. Additionally, INIS engages in contracts and partnerships with pharmaceutical companies and research institutions, providing custom isotope production services. These collaborations not only diversify their revenue but also enhance their market reach. Furthermore, INIS benefits from licensing agreements and governmental contracts, contributing to its financial stability and growth.

International Isotopes Financial Statement Overview

Summary

International Isotopes faces challenges with declining profitability and high leverage, despite some revenue growth. The income statement shows modest revenue growth but declining gross profit margins. The balance sheet reveals high leverage, and cash flow analysis indicates significant cash flow challenges.

Income Statement

The income statement shows modest revenue growth with a 3.42% increase in the TTM period. However, the gross profit margin has declined from 62.22% in 2024 to 40.28% in TTM, indicating increased cost pressures. The net profit margin remains very low at 0.35%, suggesting limited profitability. The EBIT and EBITDA margins are stable but low, reflecting operational challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.13 in TTM, though improved from 1.92 in 2024, indicating significant leverage. Return on equity is low at 1.21%, suggesting limited returns for shareholders. The equity ratio is not provided, but the overall leverage remains a concern despite some improvement.

Cash Flow

Cash flow analysis shows a significant decline in free cash flow, with a growth rate of -92.13% in TTM. The operating cash flow to net income ratio is low at 0.05, indicating weak cash generation relative to net income. Free cash flow to net income is negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.72M	13.90M	12.27M	11.18M	9.66M	9.36M
Gross Profit	6.82M	8.65M	7.38M	6.29M	5.74M	5.46M
EBITDA	881.36K	804.17K	-163.13K	1.31M	631.12K	3.59M
Net Income	122.59K	8.57K	-869.02K	-310.70K	-2.38M	-2.22M
Balance Sheet
Total Assets	17.51M	17.16M	16.91M	16.24M	16.33M	17.10M
Cash, Cash Equivalents and Short-Term Investments	1.86M	1.95M	2.69M	2.38M	474.85K	1.11M
Total Debt	4.82M	8.36M	8.34M	4.05M	4.46M	4.23M
Total Liabilities	13.24M	12.81M	12.87M	11.90M	13.60M	14.21M
Stockholders Equity	4.27M	4.35M	4.04M	4.34M	2.73M	573.55K
Cash Flow
Free Cash Flow	-36.02K	-82.43K	433.53K	-1.62M	-367.39K	1.14M
Operating Cash Flow	660.63K	638.78K	582.59K	-1.50M	-161.91K	1.15M
Investing Cash Flow	-696.65K	-685.22K	-149.06K	3.88M	-205.47K	28.26K
Financing Cash Flow	-229.81K	-145.23K	-80.50K	-472.00K	-78.70K	-637.11K

International Isotopes Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INIS, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.14 is Neutral, neither overbought nor oversold. The STOCH value of 42.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INIS.

International Isotopes Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	50 Neutral	$22.50M	-0.82	-60.76%	―	-18.05%	33.87%
RMTI	46 Neutral	$39.25M	―	-8.65%	―	-6.79%	61.56%
PRPH	45 Neutral	$16.87M	-0.23	―	―	―	―
SCYX	45 Neutral	$32.70M	-1.83	-37.22%	―	-66.30%	50.52%
TLPH	41 Neutral	$51.97M	-2.88	-117.56%	―	-93.22%	36.97%
INIS	40 Underperform	$29.05M	290.00	3.03%	―	21.26%	―

International Isotopes Corporate Events

International Isotopes CEO Signs New Employment Agreement

International Isotopes Inc. has entered into a new employment agreement with its President and CEO, Mr. Shahe Bagerdjian, effective October 10, 2025. The agreement outlines a five-year term with automatic annual renewals and includes a base salary with performance-based increases and bonuses. Additionally, Mr. Bagerdjian was awarded restricted stock units that vest upon achieving specific share price targets. On the same date, Dr. Duke W. Fu was appointed to the company’s Board of Directors. Dr. Fu, a seasoned pharmaceutical executive with extensive experience in nuclear medicine and radiopharmaceutical operations, will serve on the audit committee and receive compensation in restricted stock units.

International Isotopes Appoints New Board Director

On October 10, 2025, International Isotopes Inc. entered into a new employment agreement with Mr. Shahe Bagerdjian, who has been serving as the President and CEO since 2023. The agreement outlines his continued leadership role until 2030, with provisions for automatic annual extensions and performance-based salary increases and bonuses. Additionally, Mr. Bagerdjian was awarded restricted stock units, which vest based on the company’s share price performance and other conditions. On the same date, Dr. Duke W. Fu was appointed as a director on the company’s Board, bringing extensive experience in nuclear medicine and pharmaceutical operations. Dr. Fu’s appointment includes a compensation agreement with restricted stock units and expense reimbursements, enhancing the company’s leadership with his expertise in regulatory compliance and market expansion.